These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33032013)

  • 21. A retrospective evaluation of COVID-19 patients treated with Tocilizumab: who should be treated?
    Çelik Ekinci S; Akkaya Işık S
    J Infect Dev Ctries; 2021 Dec; 15(12):1825-1832. PubMed ID: 35044939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Tocilizumab in COVID-19: Single-Center Experience.
    Kaya S; Kavak S
    Biomed Res Int; 2021; 2021():1934685. PubMed ID: 34977235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.
    Baker EH; Patel K; Ball J; Edwards S; Harrison TS; Kaul A; Koh M; Krishna S; Leaver S; Kumar V; Forton DM
    Br J Clin Pharmacol; 2021 Mar; 87(3):1584-1586. PubMed ID: 32656822
    [No Abstract]   [Full Text] [Related]  

  • 25. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
    Cure E; Kucuk A; Cure MC
    Indian J Pharmacol; 2021; 53(3):226-228. PubMed ID: 34169908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.
    Petrak RM; Skorodin NC; Van Hise NW; Fliegelman RM; Pinsky J; Didwania V; Anderson M; Diaz M; Shah K; Chundi VV; Hines DW; Harting BP; Sidwha K; Yu B; Brune P; Owaisi A; Beezhold D; Kent J; Vais D; Han A; Gowda N; Sahgal N; Silverman J; Stake J; Nepomuceno J; Heddurshetti R
    Clin Transl Sci; 2021 Nov; 14(6):2146-2151. PubMed ID: 32918792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome.
    Oliynyk O; Barg W; Slifirczyk A; Oliynyk Y; Gurianov V; Rorat M
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34205217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
    Frigault MJ; Nikiforow S; Mansour MK; Hu ZH; Horowitz MM; Riches ML; Hematti P; Turtle CJ; Zhang MJ; Perales MA; Pasquini MC
    Blood; 2020 Jul; 136(1):137-139. PubMed ID: 32457999
    [No Abstract]   [Full Text] [Related]  

  • 29. Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes.
    Valencia Sanchez C; Theel E; Binnicker M; Toledano M; McKeon A
    Neurology; 2021 Dec; 97(23):e2262-e2268. PubMed ID: 34635560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperinflammation in COVID-19 Obese Patients Treated With Tocilizumab: A Successful Case Series.
    Beltrão BA; Teixeira RC; Porto DB
    J Investig Med High Impact Case Rep; 2021; 9():23247096211037442. PubMed ID: 34334015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.
    Jiménez-Brítez G; Ruiz P; Soler X
    Med Clin (Barc); 2020 Nov; 155(9):410-411. PubMed ID: 32718713
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Encephalopathy and COVID-19: a case report.
    Lazraq M; Benhamza S; Saadaoui S; Hayar S; Louardi M; Moujahid H; Bensaid A; Miloudi Y; Harrar NE
    Pan Afr Med J; 2021; 38():139. PubMed ID: 33912309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.
    Du P; Geng J; Wang F; Chen X; Huang Z; Wang Y
    Int J Med Sci; 2021; 18(6):1356-1362. PubMed ID: 33628091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.
    Ali A; Kamjani MH; Kesselman MM
    Recent Pat Antiinfect Drug Discov; 2020; 15(2):104-112. PubMed ID: 32962623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy.
    Lebedeva A; Molodtsov I; Anisimova A; Berestovskaya A; Dukhin O; Elizarova A; Fitzgerald W; Fomina D; Glebova K; Ivanova O; Kalinskaya A; Lebedeva A; Lysenko M; Maryukhnich E; Misyurina E; Protsenko D; Rosin A; Sapozhnikova O; Sokorev D; Shpektor A; Vorobyeva D; Vasilieva E; Margolis L
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
    Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
    Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
    [No Abstract]   [Full Text] [Related]  

  • 38. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
    Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G
    J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of tocilizumab in Hungary at a department of infectology].
    Lakatos B; Gopcsa L; Gondos E; Riczu A; Várnai Z; Nagy É; Molnár E; Bekő G; Bobek I; Reményi P; Szlávik J; Sinkó J; Vályi-Nagy I
    Orv Hetil; 2020 Jun; 161(26):1070-1077. PubMed ID: 32541085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperacute reversible encephalopathy related to cytokine storm following COVID-19 vaccine.
    Baldelli L; Amore G; Montini A; Panzera I; Rossi S; Cortelli P; Guarino M; Rinaldi R; D'Angelo R
    J Neuroimmunol; 2021 Sep; 358():577661. PubMed ID: 34284342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.